Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

A Scholz, PN Harter, S Cremer, BH Yalcin… - EMBO molecular …, 2016 - embopress.org
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of …
Save Cite Cited by 163 Related articles Library Search

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

A Scholz, PN Harter, S Cremer, BH Yalcin… - EMBO Mol …, 2016 - kups.ub.uni-koeln.de
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti-angiogenic therapy of …
Cite

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

A Scholz, PN Harter, S Cremer… - EMBO …, 2015 - publikationen.ub.uni-frankfurt.de
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of …
Cite

[CITATION][C] Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

A Scholz, PN Harter, S Cremer… - Embo Molecular …, 2016 - tobias-lib.ub.uni-tuebingen.de
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and
bevacizumab-resistant glioblastoma Endothelial cell-derived angiopoietin-2 is a therapeutic …
Cite
[HTML] embopress.org

[HTML][HTML] Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

A Scholz, PN Harter, S Cremer, BH Yalcin… - EMBO Molecular …, 2015 - embopress.org
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of …
Cite

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

A Scholz, PN Harter, S Cremer… - EMBO Molecular …, 2016 - search.proquest.com
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of …
Cite

[CITATION][C] Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

A Scholz, PN Harter, S Cremer… - Embo Molecular …, 2016 - ub01.uni-tuebingen.de
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and
bevacizumab-resistant glioblastoma Endothelial cell-derived angiopoietin-2 is a therapeutic …
Cite

[CITATION][C] Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

A Scholz, PN Harter, S Cremer, BH Yalcin… - EMBO Molecular …, 2015 - cir.nii.ac.jp
Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and
bevacizumab‐resistant glioblastoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Cite
[HTML] nih.gov

[HTML][HTML] Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

A Scholz, PN Harter, S Cremer, BH Yalcin… - EMBO Molecular …, 2016 - ncbi.nlm.nih.gov
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of …
Cite

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

A Scholz, PN Harter, S Cremer, BH Yalcin… - EMBO Molecular …, 2016 - europepmc.org
Glioblastoma multiforme (GBM) is treated by surgical resection followed by
radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of …
Cite